NH TherAguix
France - MeylanBiotechnology
Focus: NH TherAguix is a French biotech company specializing in tumor-targeting nanoparticle technology for oncology, currently advancing AGuIX across brain metastases and lung cancer indications.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at NH TherAguix?
AI assessmentBest suited for scientists/researchers seeking foundational R&D roles in nanoparticle oncology at a pre-commercial stage company; limited near-term career momentum given zero open positions.
Why Work Here
- Early-stage nanoparticle platform with focused pipeline in high-value oncology indications (brain metastases, NSCLC)
- French biotech with established clinical presence (3 active trials spanning Phase 1-2 development)
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AGuIX
Brain MetastasesClinical Trials (1)
NCT02820454Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles
Phase 1Help build intelligence for NH TherAguix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.